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Background: The hepatitis E virus (HEV) has been detected in both humans and animals, particularly pigs,
worldwide. Several evidences, including human infection following consumption of raw contaminated meat,
suggest a zoonotic transmission of HEV. In Italy, large circulation of genotype 3 HEV has been reported in swine,
and recent studies have confirmed the involvement of this genotype in autochthonous human cases.
Result: In this study 111 sera collected from healthy pigs in two Italian regions were tested for anti-HEV IgG antibodies.
For specific HEV antibody detection in swine, we developed ELISA and Western blotting methods, using a truncated
capsid (ORF2) protein lacking the first 111 amino acids of a swine HEV genotype 3 strain. The ORF2-based ELISA revealed
anti-HEV antibodies in 104 out of 111 pigs compared with 102 detected with a commercial ELISA kit. A lower number of
sera reacted with the recombinant ORF2 protein in a Western blotting format (81/111). Using a Latent class analysis (LCA),
the estimated sensitivities for ELISA-ORF2 and ELISA-kit tests were 0.961 and 0.936, respectively, whereas specificities were
0.599 and 0.475. The estimated sensitivity of Western blotting was 0.775, and the specificity was 0.944.
Conclusions: The overall results confirm the high prevalence of HEV seropositive healthy pigs in Italy. Through
comparisons with a commercial ELISA test, the swine genotype 3 HEV antigen produced in this study was proven
suitable to detect anti-HEV antibodies in pig sera by both ELISA and Western Blotting.
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Hepatitis E virus (HEV) has long been recognized as an
endemic pathogen in developing countries, involved in
large waterborne outbreaks. An increasing number of au-
tochthonous cases of hepatitis E have been recently re-
ported also in industrialized areas [1-4].
HEV is a small non enveloped RNA virus, belonging to
the Hepeviridae [5]. The genome is a single-stranded
RNA of approximately 7.3 kb, containing three open read-
ing frames (ORFs). ORF1 encodes non-structural proteins,
ORF2 the viral capsid protein, and ORF3 a cytoskeleton-
associated phosphoprotein [6]. Mammalian HEV strains
have been classified into four genotypes designated geno-
type 1 through 4 [7]. More recently, new and genetically
distant viral strains have been detected in rats [8], ferrets* Correspondence: franco.ruggeri@iss.it
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unless otherwise stated.[9], foxes [10] and bats [11], but the current HEV classifi-
cation has not been modified yet. Up to date, despite a
further classification of genotypes in subtypes, a single
serotype has been confirmed [7].
The first HEV strains infecting animals were identified in
swine [12], and later in humans [13], and were classified as
genotype 3. This HEV genotype is now recognized as the
most common one in both humans and swine in industrial-
ized countries [2,3,14-16]. Several evidences support the
zoonotic transmission of HEV from domestic pigs, wild
boar, and deer. Furthermore, the strict correlation between
animal and human strains from the same geographical
areas and the numerous reports of hepatitis E cases in
humans correlated with consumption of undercooked or
raw meat from deer, wild boar and pig contaminated with
HEV support the zoonotic transmission [4,17-20].
Usually HEV viremia and shedding have short duration
in man [21-23], whereas HEV-specific serum IgG are de-
tectable for years. The same is thought to occur inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bodies can help assess the extent of past exposure to HEV
in both individual herds and/or the overall animal popula-
tion in a country [22]. Serological HEV studies on swine
are normally conducted using commercial kits based on
human HEV antigens, but use of swine virus antigens was
proposed to increase testing sensitivity [24,25].
Several studies have been conducted in swine yielding
different HEV seroprevalence rates, but none of the tests
used was fully validated due to the absence of proper
“gold standards” [24-26].
In this study, we implemented a reliable ELISA test for
detection of anti-HEV antibodies in swine sera, using a
genotype 3 swine HEV capsid protein expressed by a re-
combinant baculovirus in insect cells as coating antigen.
We assessed the in house ELISA by a Latent class analysis
(LCA), which permits test validation in the absence of
gold standards [27]. The test was employed to evaluate the
presence of HEV antibodies in 111 swine sera collected
from different farms (No. 65) and a slaughterhouse (No.
46) in Italy. Results obtained with the ELISA based on re-
combinant swine HEV genotype 3 rΔ111ORF2 ORF2 cap-
sid protein (ELISA-ORF2) were compared with a Western
blotting (WB) test using the same antigen and with a com-
mercial ELISA kit.Results
Expression of swine HEV genotype 3 rΔ111ORF2 capsid
protein in Sf9 cells
Sf9 cells infected with the baculovirus BacHEVΔ111ORF2
expressed large amounts of the recombinant rΔ111ORF2
protein cloned from a genotype 3 HEV strain, as con-
firmed by SDS-PAGE (Figure 1A) and Western blotting
(Figure 1B). The rΔ111ORF2 protein was recognized by
an anti-HEV hyperimmune swine serum (kindly provided
by Nicole Pavio, ANSES-ENVA-INRA, Maisons-Alfort,
France) [25], but not by an SPF swine serum (not shown).Figure 1 Electrophoretic analysis of expressed HEV rΔ111ORF2 prote
protein extracts from mock infected Sf9 cells (lane 1) and cells infected wit
with Coomassie Blue for direct protein visualization, or blotted onto NC pa
serum (see Methods). The 55 kDa HEV rΔ111ORF2 protein band is indicate
PAGE and stained with Coomassie Blue, after purification using a Macro-PreThe rΔ111ORF2 protein purified from Sf9 lysates showed
a size of 55 kDa, corresponding to the capsid protein lack-
ing the first 111 amino acids.
Electron microscopic examination of ultracentrifuged in-
fected cell lysates (not shown) revealed that the rΔ111ORF2
protein did not self-assemble into virus-like particles (VLP).
For this reason, rΔ111ORF2 was concentrated and puri-
fied by ion-exchange chromatography (see Methods)
(Figure 1C). Despite the lack of VLP formation, concen-
trated rΔ111ORF2 elicited a specific immune response
in Balb/c mice, which showed serum antibody titers of
approximately 1:1000 by both ELISA-ORF2 and West-
ern blotting (not shown). These mouse sera were used
as additional positive controls throughout the study.
Seroprevalence of swine HEV antibodies
One hundred and four out of 111 (93.7%) swine sera were
positive by the ELISA-ORF2 test, whereas 102 sera were
found to be positive by the commercial ELISA (91.9%)
(Table 1). Forty of the 46 pig sera taken at slaughterhouse
had been found positive previously [16] by the commercial
ELISA kit, and were again confirmed positive by the
ELISA-ORF2 in this study despite long storage at −20°C.
All swine sera were also analyzed by Western blotting
using the rΔ111ORF2 protein. Eighty-one sera (73%)
reacted with the rΔ111ORF2 protein specifically (part of
the 81 sera are shown in Figure 2), as did the swine posi-
tive control serum. Seventy-five Western blotting positive
sera were also positive by both ELISA tests, whereas four
sera tested positive only at ELISA-ORF2, one at ELISA-
kit, and one resulted negative at both assays (Table 1).
Overall, slaughtering animals showed a seroprevalence of
86.9% (40 seropositive/46 tested), whereas all 65 farmed
swine were seropositive (seroprevalence 100%).
The mean S/CO ratios between the OD values obtained
for swine serum samples and the Cut-Off for each of the
ELISA tests were also calculated grouping samples accord-
ing to the positivity by one or both ELISA tests and WBin. SDS-PAGE (panel A) and Western blotting (panel B) of crude
h BacHEVΔ111ORF2 (lane 2). After electrophoresis, gels were stained
per for protein Immunostaining using an anti-HEV swine immune
d by an arrow. Panel C shows the rΔ111ORF2 protein separated by
p Hydroxyapatite column. MW: molecular weight markers.
Table 1 Detection of anti-HEV antibody in swine sera by ELISA-ORF2, ELISA-kit, and Western blotting assays
ELISA -ORF2 (%)* ELISA-kit (%) Western
blotting (%)






+ + + 5.40 <0.01 5.15 >0.05 75 71 1
+ + - 3.79 4.61 23 23 0.89
+ - + 4.69 >0.05 1.51 >0.05 4 5 0.98
+ - - 2.30 1.31 2 3 0.56
- + + 0.99 >0.05 2.10 >0.05 1 3 0.93
- + - 0.73 3.69 3 3 0.33
- - + 0.81 >0.05 1.80 >0.05 1 0 0.61
- - - 0.63 1.75 2 2 0.05
104 (93.7) 102 (91.9) 81 (73.0) 111
*positive/total tested.
**estimated by the model.
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WB-positive samples, a statistically significant difference
(p < 0.01) of the S/CO ratio was shown for the ELISA-
ORF2 test among samples that were positive by all three
assays.
Validity of the ELISA-ORF2 diagnostic test
The expected and observed frequencies of HEV-positive
swine sera by diagnostic test, and the probability of be-
longing to latent class HEV infection predicted by this
model are reported in Table 1. The estimated mean sen-
sitivities for ELISA-ORF2 and ELISA-kit tests were
0.961 (95% CI: 0.911-0.992) and 0.936 (95% CI: 0.880-
0.976), respectively. The estimated mean specificities of
ELISA-ORF2 and ELISA-kit tests were 0.599 (95% CI:
0.173-0.997) and 0.475 (95% CI: 0.112-0.918), respectively.
The estimated sensitivity of Western blotting was 0.775
(95%CI: 0.676-0.892), and the specificity was 0.944 (95%
CI: 0.886-0.979). The mean estimate of the posterior
probability distribution of the unbiased proportion of
seropositive swine was 0.921 (95% CI: 0.797-0.985).Figure 2 Western blotting of the HEV rΔ111ORF2 capsid protein, stai
recognized a single protein band of 55 kDa (arrow). Lane 14: swine positive
molecular weight markers.Credibility intervals (CI) were relatively large because of
the greater uncertainty related to non-informative
priors. However, the sensitivity was similar for both
ELISA tests.
Discussion
Highly sensitive molecular techniques for viral genome
identification have helped increase the detection rate of
HEV in swine, but the short duration of virus shedding
in feces represents a major limitation when investigat-
ing the prevalence of HEV infection in farms. Sero-
logical diagnosis by immunoassays can represent a valid
screening method, because HEV-specific antibodies re-
main detectable much longer than viral RNA. Although
several HEV genotypes have been described, only one viral
serotype is acknowledged to date. Tests developed for
screening human serum antibodies have consequently
been adapted to investigate also the swine by replacing the
secondary antibodies with an anti-pig Ig serum for suc-
cessful detection of specific swine antibody [28,29]. Des-
pite the cross-reaction between genotypes, immunoassaysned with swine sera from this study (lanes 1 – 13). Positive sera
control serum; lane 15: SPF swine negative control serum. MW:
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gested to provide higher sensitivity for swine serum anti-
body detection than those developed on human HEV
strains [25,28].
The expression of a N-terminal truncated form of the
ORF2 capsid protein lacking the first 111 amino acids was
previously shown to favor its self-assembly in VLPs for
both a genotype 1 HEV strain [30] and a rat HEV [31],
suggesting that post translational processing is required
for proper protein refolding [30]. Other authors [25] have
reported VLP production also from swine genotype 3
ORF2, using a similar approach. Conversely, the truncated
form of the swine genotype 3 capsid protein expressed in
this study did not self-assemble into virus-like particles,
despite being expressed in large amount. The reasons for
the failure in generating VLPs in this study are not clear,
and might involve different assembly or post-translational
modifications of the capsid protein between different geno-
types or strains of human and/or swine HEV. In fact, the
capsid proteins of human genotype 1 [30] and swine geno-
type 3 (this study) HEV shared 94.5% amino acid identity.
Nonetheless, the unassembled swine HEV protein was
recognized both efficiently and specifically by a reference
swine serum raised against the naïve virus [25], and was
highly immunogenic in mice, suggesting some extent of
folding and conservation of its antigenic structure. In a
previous study, a recombinant genotype 1 HEV peptide
(HEV 239; Hecolin; Xiamen Innovax Biotech, Xiamen,
China) was found to occur in solution as large aggregates
rather than true VLPs [32], but it was highly immuno-
genic. In this form, HEV 239 has been used as an effica-
cious recombinant hepatitis E vaccine for human use [33].
The suitability of the rΔ111ORF2 protein for testing
HEV antibody in swine sera using ELISA was confirmed
by comparing by LCA the in-house method with a com-
mercial ELISA-kit test, produced for human use and
present in the market since several years. Sensitivity of the
commercial assay is expected to be high, since antigens of
different species and strains are known to cross-react
largely, in line with the knowledge of a single serotype
among all HEV genotypes [23,34,35].
By the LC model adopted, ELISA-ORF2 and ELISA-kit
presented sensitivities of 0.961 and 0.936, and specificities
of 0.599 and 0.475, respectively. The low specificity
value for both ELISAs is due to the assumption that the
immune-stained protein band in the Western blotting
assay is 100% specific, but does not consider that Western
blotting can yield false-negative results. Therefore, the
ORF2 band absence in Western blotting using sera that
reacted in ELISA does not imply a corresponding false-
positive result of ELISA. The ELISA-kit flyers indicate that
specificity varies between 92.7 and 100% with human sera
[36-38], even if some tests can cross-react with Epstein-
Barr virus (EBV) and cytomegalovirus (CMV) antibodies,determining false positive results [39]. Therefore, it is hard
to believe that the ELISA-kit would perform very poorly
in terms of specificity only when adapted to detection of
antibodies from a different species, such as the swine.
In addition, the normalized ratios between the OD values
determined for test sera and the Cut-Off ODs for the
ELISA tests used (S/CO value) were higher for swine sera
that also proved positive at WB analysis. Although a statis-
tically different S/CO was confirmed only in the case of
ELISA-ORF2 for the more numerous group of samples that
were positive at all three tests, these results overall suggest
that positivity at WB is correlated with higher ELISA OD
values, which may imply a higher serum antibody titer.
In this study, we have determined a mean anti-HEV
seroprevalence of up to 93.7% by ELISA. No differences
were observed depending on the geographical origin of
farmed swine, whereas a lower seroprevalence of anti-
HEV IgG in pigs from slaughterhouse was observed. This
might be due to a decline of infection rate and/or immun-
ity among the older animals in this stage of pork produc-
tion [23]. In fact, most of domestic pigs get infected at 2–
3 months of age [40], and even if animals are in contact
with the virus throughout their life span they could be
seronegative at slaughtering age [41]. Furthermore, 25 of
40 (62.5%) HEV-seropositive pigs collected at slaughter-
house were found to be HEV infected by HEV genome
testing in bile, liver and/or feces [16]. This result confirms
that swine remains susceptible to HEV infection at any
age, even at slaughter, that in Italy normally involves ani-
mals of 9 months of age and more.
Conclusions
Overall the results presented in this paper confirm that
the swine HEV rΔ111ORF2 may be suitably applied to
large seroprevalence studies in pig herds using an ELISA
format. We found the in house assay to be at least as sen-
sitive as the commercial ELISA kit including a human
genotype viral antigen. These data support further that the
human and swine HEV strains belonging to different ge-
notypes are highly cross-reactive, if not even identical, in
their antigenic determinants. Finally, the use of over one-
hundred swine sera for diagnostic assays comparisons in
this study permitted to determine a mean anti-HEV sero-
prevalence of up to 93.7% among pigs which are part of
the Italian food chain, confirming the high HEV circula-
tion among Italian farmed pigs previously reported in Italy
and other countries [16,18,24,25,28].
Methods
Generation of recombinant baculovirus and expression of
HEV capsid protein
Total RNA was extracted from the HEV-positive pig bile
sample SwHEV/BO85/06 collected in Northern Italy,
using the Qiamp Viral RNA Extraction kit (Qiagen). The
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oligo(dT)20 primer and SuperScript
™III reverse tran-
scriptase (First-Strand SuperScript™III Synthesis System,
Life Technologies), following the manufacturer’s in-
structions. Amplification of an ORF2 fragment lacking
the first 333 nucleotides was performed by PCR with
primers designed on an Italian swine HEV ORF2 avail-
able in [GenBank NCBI: GU117636], denominated
FΔ111HEV (5′-GCTCTAGAGCATGGCCGTATCACC
GGCTCCCGATACA GCC-3′), flanked by XbaI restric-
tion site (italics), and RHEV (5′-GACTCGAGATTAAG
ACTC CCGGGTTTTACC-3′), flanked by XhoI site
(italics) and annealing in the ORF2 3′-terminal portion
(stop codon indicated in bold). A methionine codon (in
bold in FΔ111HEV primer) was introduced into the for-
ward primer FΔ111HEV between XbaI cleavage site and
the alanine codon at position 112. The 1652 bp DNA
fragment obtained, flanked by XbaI (italics) and XhoI
sites, was ligated into the pFastBac™1 (Life Technolo-
gies) donor vector. The construct obtained, which was
named pFast::HEVΔ111ORF2, was transformed in the
E. coli DH10Bac™ host strain containing a Baculovirus
shuttle vector (bacmid) and a helper plasmid. The recom-
binant baculovirus DNA BacHEVΔ111ORF2 was gener-
ated by transposition in the E. coli DH10Bac host, and the
resulting bacmid was purified and transfected into Sf9
cells using Cellfectin-II (Life Technologies) to produce in-
fectious recombinant baculovirus. Based on comparison of
ORF2 sequence with HEV reference strains available on
GenBank, the identity of the HEV swine strain as genotype
3 subtype e, and its correct reading frame was confirmed
[GenBank NCBI: GU556929].
Antigen preparation and purification
Sf9 cell monolayers grown in Sf900 medium (Life Tech-
nologies) in ten T75 cm2 flasks were infected with
BacHEVΔ111ORF2 baculovirus. When a diffuse cyto-
pathic effect was observed, cell cultures were lysed by
three cycles of freezing and thawing. The recombinant
protein rΔ111ORF2 was partially purified from the super-
natant by anion exchange chromatography using a Macro-
Prep Hydroxyapatite column (Bio-Rad), following the
manufacturer’s instructions. A 55 kDa protein correspond-
ing to the 111-aa deletion fragment of the capsid protein
was produced, and analyzed by SDS-PAGE.
Immunization of Balb/c mice with recombinant HEV
capsid protein
Animal work was conducted according to the Italian legis-
lation enacting the EU directives (D.L. 116/92), following
approval of the specific experimental protocols (mouse
immunization and serum withdrawal, granted to Franco
Maria Ruggeri) by the Biological and Animal Experimental
Managing Service of the Istituto Superiore di Sanità andthe legal authorization by the Italian Ministry of Health
(Decree no. 97/2011 – B, 24th May 2011).
Three adult Balb/c mice (12 week-old) were immunized
three times intraperitoneally at 3-week intervals with
15 μg of purified HEV capsid protein, in the presence of
complete Freund’s adjuvant for the first inoculation, and
incomplete adjuvant for the following immunizations.
A mouse inoculated with sterile saline solution was used
as negative control. Fourteen days after the final boosting,
sera were tested for anti-HEV antibodies by Western blot-
ting, as described below [25]. Mice were euthanized fol-
lowing isoflurane anesthesia, and serum was collected
from the intracardiac clot.
Swine sera
Sixty-five sera were aliquots from a larger sample of sera
previously analyzed and stored within the regional monitor-
ing plan for African swine fever (ASF) and Classical swine
fever (CSF) enforced in Sardinia, in compliance with the
European Community requirements. Sera had been col-
lected from clinically healthy pigs by staff veterinarians of
the Italian Public Health System (ASL), according to De-
crees No. 9, 16.05.2007, and No. 1567/decA/23, 14.07.2009,
of the “Assessorato dell’Igiene e Sanità e dell’Assistenza
Sociale, Regione Autonoma della Sardegna”, at five farms
located in different areas in Sardinia [42]. Additional 46
sera had been collected post-mortem from the intracar-
diac clot of slaughtered pigs at pork slaughterhouses in
Northern Italy [16]. Sera were stored at −20°C until use.
Western blotting
Purified rΔ111ORF2 was separated by SDS-PAGE, and
either stained with Coomassie Brilliant Blue R-250 (Bio-
Rad), or transferred to nitrocellulose membrane (Trans-
blot transfer medium, Bio-Rad). After blocking with 5%
skim milk in phosphate-buffered saline (PBS), the mem-
brane was incubated with test (diluted 1:160) or control
(1:1000) sera in PBS containing 0.05% Tween-20 and
1% skim milk, for 4 hours. Three sera from Specific
Pathogen Free (SPF) pigs were used as negative control,
while an experimentally infected swine serum [25] and a
hyperimmune anti-HEVORF2 mouse serum were used as
positive controls. Membranes were then incubated with
alkaline phosphatase-conjugated anti-pig IgG (1:12000;
SIGMA) or anti-mouse IgG (1:3000; Bio-Rad). Bands were
visualized with 1-step NBT/BCIP solution (Pierce).
Recombinant ORF2-based ELISA procedure (ELISA-ORF2)
Polystyrene 96-well microplates (Maxisorp, Nunc) were
coated with purified rΔ111ORF2 (0.01 μg/well). A control
plate was coated with an Sf9 lysate containing an irrele-
vant protein (bovine norovirus capsid) [43]. After 18 hours
at 4°C, wells were washed 3 times with PBS containing
0.05% Tween-20 (PBS-T), and blocked with 5% skim milk
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cubated with test sera diluted 1:20 in PBS containing
0.05% Tween-20 and 2% skim milk (PBS-T-milk), at 37°C
for 90 min, in triplicate. Swine positive and control sera
were used in all tests.
After washing with PBS-T, anti-pig (1:12000) and anti-
mouse (1:3000) conjugates were added. Following 1 hour
incubation at 37°C and washings, the reaction was devel-
oped with p-nitrophenol phosphate (SIGMA) in 10 mM
diethanolamine, pH 10, for 1 hour at 37°C. Optical dens-
ities were measured at a wavelength of 405 nm (OD405).
The Cut-Off value (COV) for the ELISA-ORF2 was estab-
lished from internal controls for each test, using the com-
mercial ELISA test formula: [mean OD of negative
controls + 0.1]. Throughout this study, this value was 0.18.
Commercial ELISA test (ELISA-kit)
Swine sera (diluted 1:20) were also tested by the BioChain
kit (www.biochain.com, USA), commercially available for
anti-HEV IgG detection in human sera, with the following
modifications: the secondary antibody was replaced with a
horseradish peroxidase-labeled anti-swine IgG antibody
(SIGMA), diluted 1:10000. Test sera were considered as
positive if OD450 ≥COV, as indicated by the kit manufac-
turer. Positive and negative swine control sera (see above)
were included in all assays.
All reporting adheres to the NC3Rs ARRIVE guide-
lines (Animal Research: Reporting In Vivo Experiments)
(Additional file 1).
Statistical analysis
A Bayesian approach was used to obtain estimates for
the test accuracies of the three tests. The data were
processed with Bayes Latent Class Models software
(http://www.medicine.mcgill.ca/epidemiology/Joseph/
Bayesian-Software-Diagnostic-Testing.html). Param-
eter estimates were based on analytical summaries of
10,000 iterations of the Gibbs sampler with a burn-in
phase of 1000 iterations.
Sensitivity and specificity were estimated by the classic
validation method as well as by Latent-class analysis
modeling. In Latent class analysis (LCA), we started by
fitting the basic two latent class model.
Beta distributions Be (a, b) were used as priors for the pa-
rameters of interest (sensitivities, and specificities). The
same Beta prior distributions [25] were used for the sensi-
tivities of both ELISA tests: >0.6; mode = 0.9 corresponding
to Be (8.30, 1.81) priors. For both ELISA tests a uniform
prior distribution for specificity Be (0, 1) was assumed.
Swine sera testing by HEV WB were considered 100%
specific. The Beta prior distribution for WB specificity
had mode = 0.9 and a 5th percentile of 0.9. For WB tests
we assumed a uniform prior distribution for sensitivity
Be (0, 1).Sensitivity and specificity of tests were reported with
an approximate 95% confidence interval (CI), as esti-
mated by the model.
Additional file
Additional file 1: NC3Rs ARRIVE Guidelines Checklist.
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